Combination therapy shows promise in early breast tumors

January 7, 2015 11:24 PM

15 0

Treatment combining low-dose chemotherapy and the targeted drug trastuzumab showed promise in women with early stage breast cancer of a type called HER2-positive, US researchers said Wednesday.

Women receiving the treatment were highly unlikely to see their cancer return, said the study in the New England Journal of Medicine analyzing a regimen that including the chemotherapy agent paclitaxel and the targeted drug under the brand name Herceptin.

Also read: Gene editing tool may raise cancer risk in cells, scientists warn

Read more

To category page